IdentifAI Genetics Overview
Identifai Genetics is developing a noninvasive prenatal test for the early detection of single-gene disorders. Using a simple first-trimester maternal blood test to access the entire embryonic genome, Identifai can perform a comprehensive analysis capable of detecting every single-point mutation, insertion-deletion, and structural variation in order to identify severe genetic disorders. Identifais core suite of algorithms, the Hoobari paradigm, is a patent-pending proprietary methodology developed for five years at Tel Aviv University. The technology has demonstrated high accuracy in detecting a wide variety of mutations in real-life cases, and the company is planning to launch clinical studies. Identifai Genetics is dedicated to providing solutions that will enable safe pregnancies for all families, everywhere.
Cumulative Funding Raised Over Time ($)
$3.3MApr 2023
$3.7MJan 2021
$5.0MOct 2021
Latest News
growth-positive
לראשונה בעולם: טכנולוגיה מהפכנית תזהה סיכון למאות מחלות גנטיות - טכנולוגיה
Identifai, an Israeli startup founded in 2021, has developed a groundbreaking AI technology for prenatal genetic testing. This technology can identify the risk of hundreds of genetic diseases in a 9-week-old fetus using a simple blood test from the mother. The innovation, based on research by Prof. Noam Shomron and Dr. Tom Rabinowitz, allows for full genetic sequencing of fetal DNA, offering a non-invasive alternative to traditional amniocentesis. Identifais technology has already gained global recognition and is undergoing further trials in the U.S. The company has raised $6.5 million from investors like eHealth Ventures and Shizim, and plans to expand its workforce and partnerships with major U.S. companies. Identifai aims to launch its product by 2025, potentially revolutionizing the $6 billion prenatal testing market.
InvestmentPartnersExpand
growth-positive
Israeli startup develops AI to detect 250 genetic diseases in fetuses from maternal blood | CTech
IdentifAI, an Israeli health-tech company, has developed a groundbreaking non-invasive prenatal testing (NIPT) technology that can identify 250 hereditary genetic disorders from a maternal blood sample. This advancement significantly expands current NIPT capabilities, which are limited to detecting about 25 genetic conditions. The technology uses artificial intelligence and machine learning to isolate fetal DNA and conduct full genetic sequencing as early as nine weeks into pregnancy. Clinical trials in Israel and the U.S. have demonstrated the systems accuracy. IdentifAI has raised $6.5 million from investors, including eHealth Ventures and Shizim Fund, and employs 15 people in Tel Aviv. The NIPT market is projected to grow from $6 billion to $19 billion by 2030, driven by technological advances and increased demand for non-invasive solutions.
InvestmentCustomers
growth-positive
Decoding DNA To Identify Birth Defects In Unborn Babies
Israeli startup Identifai Genetics has developed a simple and inexpensive blood test to determine whether a baby will be born with any genetic disorder. The test analyzes traces of the fetus DNA found in the mothers blood and can be completed in the first trimester of pregnancy, providing faster results compared to current testing methods. Identifai aims to widen the prospects for treatment by catching genetic defects early, allowing for potential interventions or treatments. The company, founded in 2019, has conducted clinical trials in Israeli hospitals and plans to begin its first US-based trial in collaboration with Columbia University and Lenox Hill Hospital. Identifai hopes to make its genetic testing available for clinical use within 18 months.
Customers
growth-positive
Identifai-Genetics Closes a USD 3.3M Post-Seed Funding
Identifai-Genetics, a Tel Aviv-based developer of AI-based solutions for non-invasive fetal DNA sequencing, has raised USD 3.3M in Post-Seed funding. The funding round was led by eHealth Ventures and included Dr. Ron Sabar. The company plans to use the funds to expand its operations and R&D efforts. Identifai offers solutions for the non-invasive detection of fetal genetic disorders using a risk-free blood test from the mother. The company has recently engaged HcFocusTM, founded by Dr. Susan Gross, as Chief Strategic Advisor. Identifai has raised over $6M in equity investments and R&D grants.
InvestmentExpand
growth-positive
Assuta's 'RISE with US' launches with six startups looking for international markets | CTech
Assutas innovation arm RISE has launched a program called RISE with US in collaboration with the University City Science Center. The program aims to help startups in the healthcare sector penetrate international markets. Six companies were selected for the program, focusing on digital health solutions. The program operates in partnership with technology companies such as AWS and NVIDIA, as well as venture capital fund LionBird and law firms Reinhold Cohn & Co. and Naomi Asia & Co. Participants will receive mentorship, access to a network of contacts, and clinical mentorship from doctors. The partnership also provides access to hospitals, insurers, and academic centers in the Philadelphia area. The program aims to support the development and commercialization of the startups technologies.
PartnersExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $9.25M |
| Last funding | $1M |
| Stage | Seed |
| Rounds | 6 |
| Investors | 3 |
Team Members
6
Employees: 11-50
Web & Social Links
| Website | identifai-genetics.com/ |
| Careers | Careers page |
Locations
HaMelacha Street 22, Rosh Haayin, Israel
Photos & Videos
No files yet
IdentifAI Genetics Business
Business models
B2B2C, B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyTest Diagnostics & ScreeningTarget Customer
Healthcare & Life SciencesHealthcareInsurance CompaniesLaboratoriesPatientsProvidersLife SciencesBiotechnologyCore Technology
BiologicalsGenesArtificial IntelligenceMachine LearningDeep LearningTags (17)
femtechpregnancygeneticsmachine-learningdeep-learningdiagnosticsartificial-intelligencewomen-healthbiotechnologygenetic-disordersnon-invasivebabiesblood-testearly-detectionhealthcare-providerswomenpharmaceuticalsGeographic Markets
EuropeNorth AmericaAsiaIdentifAI Genetics Financials
$9.25M
Total funding
Undisclosed
Capital raised
$1M
Last funding
Seed
Funding stage
6
Total rounds
3
Investors
Cumulative Funding Raised Over Time ($)
$3.3MApr 2023
$3.7MJan 2021
$5.0MOct 2021
Private Equity Funding
Seed
Apr 2023
$3.3M
eHealth Ventures (Lead)
Seed
Oct 2021
$1.3M
Undisclosed Investor(s)
Pre-Seed
Jan 2021
$400K
Shizim Group (Lead)
Non-Equity Funding
GrantEvent
Jul 2024
$1M
GrantEvent
Feb 2023
$2.5M
Israel Innovation Authority (Lead)
GrantEvent
Dec 2021
$750K
IIA
IdentifAI Genetics Lifecycle
Cumulative Funding Raised Over Time
$3.3MApr 2023
$3.7MJan 2021
$5.0MOct 2021
All Events
Seed
Apr 2023
$3.3M
eHealth Ventures (Lead)
Seed
Oct 2021
$1.3M
Undisclosed Investor(s)
Pre-Seed
Jan 2021
$400K
Shizim Group (Lead)
GrantEvent
Jul 2024
$1M
GrantEvent
Feb 2023
$2.5M
Israel Innovation Authority (Lead)
GrantEvent
Dec 2021
$750K
IIA
IdentifAI Genetics News
9 articles
growth-positive
לראשונה בעולם: טכנולוגיה מהפכנית תזהה סיכון למאות מחלות גנטיות - טכנולוגיה
Identifai, an Israeli startup founded in 2021, has developed a groundbreaking AI technology for prenatal genetic testing. This technology can identify the risk of hundreds of genetic diseases in a 9-week-old fetus using a simple blood test from the mother. The innovation, based on research by Prof. Noam Shomron and Dr. Tom Rabinowitz, allows for full genetic sequencing of fetal DNA, offering a non-invasive alternative to traditional amniocentesis. Identifais technology has already gained global recognition and is undergoing further trials in the U.S. The company has raised $6.5 million from investors like eHealth Ventures and Shizim, and plans to expand its workforce and partnerships with major U.S. companies. Identifai aims to launch its product by 2025, potentially revolutionizing the $6 billion prenatal testing market.
InvestmentPartnersExpand
growth-positive
Israeli startup develops AI to detect 250 genetic diseases in fetuses from maternal blood | CTech
IdentifAI, an Israeli health-tech company, has developed a groundbreaking non-invasive prenatal testing (NIPT) technology that can identify 250 hereditary genetic disorders from a maternal blood sample. This advancement significantly expands current NIPT capabilities, which are limited to detecting about 25 genetic conditions. The technology uses artificial intelligence and machine learning to isolate fetal DNA and conduct full genetic sequencing as early as nine weeks into pregnancy. Clinical trials in Israel and the U.S. have demonstrated the systems accuracy. IdentifAI has raised $6.5 million from investors, including eHealth Ventures and Shizim Fund, and employs 15 people in Tel Aviv. The NIPT market is projected to grow from $6 billion to $19 billion by 2030, driven by technological advances and increased demand for non-invasive solutions.
InvestmentCustomers
growth-positive
Decoding DNA To Identify Birth Defects In Unborn Babies
Israeli startup Identifai Genetics has developed a simple and inexpensive blood test to determine whether a baby will be born with any genetic disorder. The test analyzes traces of the fetus DNA found in the mothers blood and can be completed in the first trimester of pregnancy, providing faster results compared to current testing methods. Identifai aims to widen the prospects for treatment by catching genetic defects early, allowing for potential interventions or treatments. The company, founded in 2019, has conducted clinical trials in Israeli hospitals and plans to begin its first US-based trial in collaboration with Columbia University and Lenox Hill Hospital. Identifai hopes to make its genetic testing available for clinical use within 18 months.
Customers
growth-positive
Identifai-Genetics Closes a USD 3.3M Post-Seed Funding
Identifai-Genetics, a Tel Aviv-based developer of AI-based solutions for non-invasive fetal DNA sequencing, has raised USD 3.3M in Post-Seed funding. The funding round was led by eHealth Ventures and included Dr. Ron Sabar. The company plans to use the funds to expand its operations and R&D efforts. Identifai offers solutions for the non-invasive detection of fetal genetic disorders using a risk-free blood test from the mother. The company has recently engaged HcFocusTM, founded by Dr. Susan Gross, as Chief Strategic Advisor. Identifai has raised over $6M in equity investments and R&D grants.
InvestmentExpand
growth-positive
Assuta's 'RISE with US' launches with six startups looking for international markets | CTech
Assutas innovation arm RISE has launched a program called RISE with US in collaboration with the University City Science Center. The program aims to help startups in the healthcare sector penetrate international markets. Six companies were selected for the program, focusing on digital health solutions. The program operates in partnership with technology companies such as AWS and NVIDIA, as well as venture capital fund LionBird and law firms Reinhold Cohn & Co. and Naomi Asia & Co. Participants will receive mentorship, access to a network of contacts, and clinical mentorship from doctors. The partnership also provides access to hospitals, insurers, and academic centers in the Philadelphia area. The program aims to support the development and commercialization of the startups technologies.
PartnersExpand
growth-positive
New blood test may detect fetal abnormalities at week 10 - ISRAEL21c
IdentifAI Genetics, a startup founded by Prof. Noam Shomron, has developed a blood test called Hoobari that can detect genetic problems in fetuses as early as week 10 of pregnancy. The test is noninvasive and has a success rate of nearly 100%. It distinguishes between the mothers DNA and fragments of DNA from the embryo, allowing for accurate detection of genetic anomalies. IdentifAI Genetics is targeting OB-GYNs as its first customers, with the United States as its main market. The company has raised $2.5 million in funding from the Israel Innovation Authority and private investors. In addition to prenatal testing, IdentifAI plans to use its technology to detect cancer mutations in the future.
Customers
growth-positive
"In the coming years we will eliminate the need for amniocentesis" | CTech
IdentifAI Genetics, a company specializing in genetic sequencing, has developed a technology that allows for full genetic sequencing of the fetus using a simple blood test from the mother. The technology has close to 100% accuracy and is non-invasive. The company plans to bring the product to market within two years. Other companies discussed in the article include POLOPO, Urbanico, EyeLight Technologies, Pickommerce AI Robotics, and Blyp. POLOPO is approaching food industry companies for partnerships, Urbanico solves problems for insurance companies using urban information, EyeLight Technologies provides real-time object identification for the visually impaired, Pickommerce AI Robotics focuses on the packaging problem in e-commerce, and Blyp offers automatic analysis of business data.
Expand
growth-positive
Israeli AI can identify genetic disorders in embryo with simple blood te
Israeli startup IdentifAI Genetics is developing a non-invasive early detection method using artificial intelligence (AI) to identify genetic disorders in human embryos. The technology involves a simple blood test taken from the pregnant mother during the first trimester to read the embryos entire DNA and provide in-depth analysis. The procedure is non-invasive and carries no risk for the pregnancy, unlike existing methods like amniocentesis. IdentifAI Genetics aims to bring the product to market within two years and is also exploring the potential for early cancer detection. The company relies on a new AI-based software tool known as Hoobari, developed by Tel Aviv University.
Customers
growth-positive
IdentifAI Genetics on LinkedIn: Happy and excited to announce and share with you: IdentifAI wins today
IdentifAI Genetics announces winning 1st prize at the annual Reinhold Cohn & HealthIL startup competition. The company is pushing forward its disruptive technology aimed at benefiting pregnant women worldwide. IdentifAI Genetics also mentions participating in the ISPD conference, BioMed 2023, and the Rise program. They invite others to join them at these events to discuss innovative ideas and potential collaborations. The company is proud to reach the finals of the startup competition organized by Calcalist and Poalim Hi-Tech. They highlight their goal of offering the first full fetal DNA examination using a simple blood test from the mother. IdentifAI Genetics expresses gratitude to their team, collaborators, and competition organizers.
Partners
IdentifAI Genetics Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 14 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 16 classification IDs that could be used for matching.
IdentifAI Genetics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 97/100 |
| Missing | video or image, markets |
| BI Verification | Yotam Maman |
| Registrar ID | 516377033 |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-07-24T00:00:00.000Z |
| Created | 2021-07-12T00:00:00.000Z |
| Claimed | Yes |